Table 2.
Sensitivities of 18F-FDG and 68Ga-FAPI-04 PET/CT in patient-based analysis.
| Patient characteristics | No. of patients | No. oflesions | 18F-FDG | 68Ga-FAPI-04 | P between 2 tracers | ||
|---|---|---|---|---|---|---|---|
| Positive lesions (%) | P | Positive lesions (%) | P | ||||
| All | 25 | 35 | 20 (57.1) | 30 (85.7) | 0.002* | ||
| Clinical features | |||||||
| Cirrhosis | 19 | 29 | 16 (55.2) | 0.680 | 24 (82.8) | 0.561 | 0.008* |
| Non-cirrhosis | 6 | 6 | 4 (66.7) | 6 (100) | 0.500 | ||
| AFP (ng/mL) | |||||||
| ≤ 20 | 13 | 17 | 11 (64.7) | 0.500 | 17 (100) | 0.045* | 0.031* |
| > 20 | 12 | 18 | 9 (50.0) | 13 (72.2) | 0.125 | ||
| Tumour number | |||||||
| Solitary tumour | 15 | 15 | 10 (66.7) | 0.492 | 14 (93.3) | 0.365 | 0.125 |
| Multiple tumours | 10 | 20 | 10 (50.0) | 16 (80.0) | 0.031* | ||
| MVI | |||||||
| M0 + M1 | 10 | 14 | 4 (28.6) | 0.057 | 10 (71.4) | 0.326 | 0.031* |
| M2 | 10 | 14 | 10 (71.4) | 13 (92.9) | 0.250 | ||
| AJCC TNM staging | |||||||
| I | 5 | 5 | 0 (0) | 0.016* | 4 (80.0) | 0.423 | 0.125 |
| II | 10 | 16 | 8 (50.0) | 12 (75.0) | 0.125 | ||
| III + IV | 5 | 7 | 6 (85.7) | 7 (100) | 1 | ||
Five HCC patients whose diagnosis was based on non-invasive criteria underwent TACE instead of hepatic surgery and, therefore, had no pathological data. *, statistically significant; AFP, α-fetoprotein; MVI, microvascular invasio; AJCC TNM, American Joint Committee on Cancer tumour-node-metastasis.